DE2023987C3 - Verfahren zur Spaltung von Viren - Google Patents
Verfahren zur Spaltung von VirenInfo
- Publication number
- DE2023987C3 DE2023987C3 DE2023987A DE2023987A DE2023987C3 DE 2023987 C3 DE2023987 C3 DE 2023987C3 DE 2023987 A DE2023987 A DE 2023987A DE 2023987 A DE2023987 A DE 2023987A DE 2023987 C3 DE2023987 C3 DE 2023987C3
- Authority
- DE
- Germany
- Prior art keywords
- virus
- viruses
- influenza
- intact
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000700605 Viruses Species 0.000 title claims description 71
- 238000000034 method Methods 0.000 title claims description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- 229910019142 PO4 Inorganic materials 0.000 claims description 17
- 239000010452 phosphate Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 14
- 241000712461 unidentified influenza virus Species 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 10
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 7
- 206010022000 influenza Diseases 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 206010037660 Pyrexia Diseases 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 235000013601 eggs Nutrition 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 102000005348 Neuraminidase Human genes 0.000 claims description 3
- 108010006232 Neuraminidase Proteins 0.000 claims description 3
- 241000711798 Rabies lyssavirus Species 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012531 culture fluid Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 239000002510 pyrogen Substances 0.000 claims description 3
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims 7
- 241000699670 Mus sp. Species 0.000 claims 2
- 239000006286 aqueous extract Substances 0.000 claims 2
- 229960003964 deoxycholic acid Drugs 0.000 claims 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
- 239000003599 detergent Substances 0.000 claims 2
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 241000710188 Encephalomyocarditis virus Species 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 208000010359 Newcastle Disease Diseases 0.000 claims 1
- 206010037742 Rabies Diseases 0.000 claims 1
- 241000710888 St. Louis encephalitis virus Species 0.000 claims 1
- 241000223777 Theileria Species 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003837 chick embryo Anatomy 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 229940124452 immunizing agent Drugs 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 229940031626 subunit vaccine Drugs 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
- -1 phosphate ester Chemical class 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 6
- AZSFNUJOCKMOGB-UHFFFAOYSA-K cyclotriphosphate(3-) Chemical compound [O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 AZSFNUJOCKMOGB-UHFFFAOYSA-K 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- KUHPLTBUBAGTDV-UHFFFAOYSA-N tris-decyl phosphate Chemical compound CCCCCCCCCCOP(=O)(OCCCCCCCCCC)OCCCCCCCCCC KUHPLTBUBAGTDV-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- GTVWRXDRKAHEAD-UHFFFAOYSA-N Tris(2-ethylhexyl) phosphate Chemical compound CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC GTVWRXDRKAHEAD-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- SFENPMLASUEABX-UHFFFAOYSA-N trihexyl phosphate Chemical compound CCCCCCOP(=O)(OCCCCCC)OCCCCCC SFENPMLASUEABX-UHFFFAOYSA-N 0.000 description 1
- CQXYINNETWHZTR-UHFFFAOYSA-N tritert-butyl phosphate Chemical compound CC(C)(C)OP(=O)(OC(C)(C)C)OC(C)(C)C CQXYINNETWHZTR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82678369A | 1969-05-16 | 1969-05-16 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2023987A1 DE2023987A1 (de) | 1970-12-17 |
| DE2023987B2 DE2023987B2 (de) | 1978-09-07 |
| DE2023987C3 true DE2023987C3 (de) | 1979-05-03 |
Family
ID=25247524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2023987A Expired DE2023987C3 (de) | 1969-05-16 | 1970-05-15 | Verfahren zur Spaltung von Viren |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE2023987C3 (forum.php) |
| FR (1) | FR2051533B1 (forum.php) |
| GB (1) | GB1292197A (forum.php) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE661402A (forum.php) * | 1964-03-20 |
-
1970
- 1970-05-12 GB GB2275770A patent/GB1292197A/en not_active Expired
- 1970-05-15 FR FR7017848A patent/FR2051533B1/fr not_active Expired
- 1970-05-15 DE DE2023987A patent/DE2023987C3/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE2023987B2 (de) | 1978-09-07 |
| GB1292197A (en) | 1972-10-11 |
| DE2023987A1 (de) | 1970-12-17 |
| FR2051533A1 (forum.php) | 1971-04-09 |
| FR2051533B1 (forum.php) | 1974-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3962421A (en) | Method for the disruption of lipid-containing viruses | |
| EP0011243B1 (de) | Verfahren zur Herstellung von Membranproteinen aus Neisseria meningitidis und diese enthaltende Vaccine | |
| DE2954387C2 (de) | Die tumorspezifische Immunität vergrößernder Bakterienzellenextrakt und Verfahren zu seiner Herstellung | |
| DE60005241T2 (de) | Verfahren zur Herstellung von Phosphatidylserinen | |
| DE2517596C2 (de) | (R)-3-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo [4,5-d] [1,3]diazepin-8-ol und Verfahren zu dessen Herstellung | |
| DE2457090C2 (de) | Verfahren zur Herstellung von Impfstoffen sowie Antibronchialimpfstoff | |
| DE2833545A1 (de) | Hochmolekulare meningokokken- gruppe c-vaccine und verfahren zu ihrer herstellung | |
| DE3152621C2 (forum.php) | ||
| DE2355094A1 (de) | Tetanus-vaccine und verfahren zu deren herstellung | |
| DD155875A1 (de) | Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes | |
| DE2023987C3 (de) | Verfahren zur Spaltung von Viren | |
| DE1198489B (de) | Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie | |
| DE2950004C2 (de) | Verfahren zur Herstellung von Frühsommer-Meningoenzephalitis-Virus(FSME-Virus)-Vakzinen | |
| DD300833A7 (de) | Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen | |
| US2074492A (en) | Medicinal compound | |
| DE2111120C3 (de) | Verfahren zur Herstellung von Rubella-Virus-Hämagglutinationsantigen | |
| DE1927802C2 (de) | DHO-Prostadiensäure sowie diese enthaltende pharmazeutische Präparate | |
| DE19938767C2 (de) | Spaltimpfstoffe | |
| DE947192C (de) | Verfahren zur Herstellung eines Heilserums zur Therapie des Rheumatismus, insbesondere der primaer chronischen Polyarthritis | |
| CH433595A (de) | Verfahren zur Herstellung eines Trachom-Schutzimpfstoffes | |
| DE248984C (forum.php) | ||
| DE2220053C3 (de) | Mittel zur aktiven und passiven Immunisierung gegen die toxischen Effekte von Infektionen durch Elastase bildende Bakterien und Verfahren zur Herstellung derselben | |
| DE1247548B (de) | Verfahren zur Herstellung einer Masern-Vaccine | |
| CH263036A (de) | Verfahren zur Extraktion von Nucleotide enthaltendem Material. | |
| DE1011117B (de) | Verfahren zur Herstellung von reinen stabilen Erythromycin-Saeure-Additionssalzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: SCHWABE, H., DIPL.-ING. SANDMAIR, K., DIPL.-CHEM. DR.JUR. DR.RER.NAT. MARX, L., DIPL.-PHYS. DR.RER.NAT., PAT.-ANW., 8000 MUENCHEN |